Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00096941
Status:
COMPLETED
Last Update Posted:
2015-06-11
First Post:
2004-11-17
Brief Title:
A Study to Evaluate Subjects Treated With rhuMab 2C4 Pertuzumab in a Previous Genentech Phase II Cancer Study
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
An Open-Label Multicenter Extension Study of Pertuzumab rhuMAb 2C4 in Subjects Treated With Pertuzumab in a Previous Genentech-Sponsored Phase II Cancer Study
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter open label extension study Subjects who have completed treatment in the parent study of pertuzumab either alone or with a combination agent and who received at least one dose of pertuzumab in the parent study are eligible for inclusion in this trial if they are continuing to receive clinical benefit
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None